Dr. Roberto Pili, MD (Hematology/Oncology) and Dr. David Heppner, PhD (Chemistry) have teamed up to develop treatments against an aggressive form of kidney cancer. The project has been awarded a five-year $1.8M NIH R01 National Cancer Institute R01 shared between the collaborating labs to advance drug discovery in a cancer type where limited therapeutic options are available.
Read more about this collaborative work.